Quick Answer
Arcadia Biosciences, Inc. reported Total Revenue of $4.86 million for fiscal year 2025.
Arcadia Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.86M -3.7% |
$5.04M +13.3% |
$4.45M -40.0% |
$7.42M +9.4% |
$6.78M -15.6% |
$8.03M +587.3% |
| Revenue (ASC 606) | $4.86M -3.7% |
$5.04M +13.3% |
$4.45M -40.0% |
$7.42M +9.4% |
$6.78M -15.6% |
$8.03M +587.3% |
| Net Income | -$2.34M +66.8% |
-$7.04M +49.7% |
-$13.98M +9.1% |
-$15.38M -4.9% |
-$14.66M -214.9% |
-$4.66M +83.8% |
| Diluted EPS | -$1.71 +66.9% |
-$5.17 +54.2% |
-$11.29 +56.0% |
-$25.65 +6.9% |
-$27.56 | — |
| Total Assets | $6.55M -51.6% |
$13.52M -31.4% |
$19.70M -31.9% |
$28.92M -34.1% |
$43.92M -7.2% |
$47.35M +45.4% |
| Cash and Equivalents | $259.0K -93.9% |
$4.24M -34.9% |
$6.52M -68.4% |
$20.64M -28.0% |
$28.68M +104.3% |
$14.04M +66.8% |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$2.10M +1867.3% |
| Stockholders Equity | $4.14M -33.5% |
$6.22M -51.5% |
$12.84M -38.9% |
$21.03M -32.4% |
$31.09M +12.1% |
$27.73M +259.8% |
| R&D Expense | $9.0K -83.0% |
$53.0K -17.2% |
$64.0K -95.8% |
$1.51M -61.2% |
$3.89M -51.1% |
$7.96M +12.1% |
| Operating Income | -$2.50M +31.5% |
-$3.65M +40.2% |
-$6.10M +56.4% |
-$14.01M +60.6% |
-$35.53M -178.0% |
-$12.78M +34.1% |
| Shares Outstanding | 1.37M +0.6% |
1.36M +6.2% |
1.29M +108.6% |
616,079 +11.1% |
554,609 -95.9% |
13.45M +55.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.30M | -15.3% | -10.5% |
| Revenue (ASC 606) | September 30, 2025 | $1.30M | -15.3% | -10.5% |
| Net Income | September 30, 2025 | $856.0K | +153.1% | +119.2% |
| Diluted EPS | September 30, 2025 | $0.62 | +152.5% | +119.0% |
| Total Assets | September 30, 2025 | $8.58M | -43.7% | +10.2% |
| Cash and Equivalents | September 30, 2025 | $1.12M | -71.5% | -18.6% |
| Long-Term Debt | September 30, 2021 | $78.0K | -96.9% | -10.3% |
| Stockholders Equity | September 30, 2025 | $5.44M | -47.1% | +20.1% |
| R&D Expense | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Operating Income | September 30, 2025 | -$1.15M | +34.5% | -129.9% |
| Shares Outstanding | September 30, 2025 | 1.37M | +0.2% | +0.0% |
- Arcadia Biosciences, Inc. reported Total Revenue of $4.86 million for fiscal year 2025.
- Arcadia Biosciences, Inc. showed a decrease of -3.7% in Total Revenue compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Revenue (ASC 606) of $4.86 million for fiscal year 2025.
- Arcadia Biosciences, Inc. showed a decrease of -3.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Net Income of -$2.34 million for fiscal year 2025.
- Arcadia Biosciences, Inc. showed an increase of +66.8% in Net Income compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Diluted EPS of $1.71 per share (loss) for fiscal year 2025.
- Arcadia Biosciences, Inc. showed an increase of +66.9% in Diluted EPS compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Total Assets of $6.55 million for fiscal year 2025.
- Arcadia Biosciences, Inc. showed a decrease of -51.6% in Total Assets compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Cash and Equivalents of $259.0 thousand for fiscal year 2025.
- Arcadia Biosciences, Inc. showed a decrease of -93.9% in Cash and Equivalents compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
- Arcadia Biosciences, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Stockholders Equity of $4.14 million for fiscal year 2025.
- Arcadia Biosciences, Inc. showed a decrease of -33.5% in Stockholders Equity compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported R&D Expense of $9.0 thousand for fiscal year 2025.
- Arcadia Biosciences, Inc. showed a decrease of -83.0% in R&D Expense compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Operating Income of -$2.50 million for fiscal year 2025.
- Arcadia Biosciences, Inc. showed an increase of +31.5% in Operating Income compared to the prior fiscal year.
- Arcadia Biosciences, Inc. reported Shares Outstanding of 1.37 million shares for fiscal year 2025.
- Arcadia Biosciences, Inc. showed an increase of +0.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: